Document Detail


Prednisolone in Bell's palsy related to treatment start and age.
MedLine Citation:
PMID:  21099725     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate if treatment start and age are related to the outcome in Bell's palsy patients treated with prednisolone.
STUDY DESIGN: Prospective, randomized, double-blind, placebo-controlled, multicenter trial.
SETTING: Sixteen otorhinolaryngologic centers in Sweden and 1 in Finland.
PATIENTS: Data were collected from the Scandinavian Bell's palsy study. A total of 829 patients were treated within 72 hours of onset of palsy. Follow-up was 12 months.
INTERVENTION: Patients were randomly assigned to treatment with placebo plus placebo (n = 206), prednisolone plus placebo (n = 210), valacyclovir plus placebo (n = 207), or prednisolone plus valacyclovir (n = 206).
MAIN OUTCOME MEASURES: Facial function was assessed with the Sunnybrook grading system, and complete recovery was defined as Sunnybrook = 100. Time from onset of palsy to treatment start was registered.
RESULTS: Patients treated with prednisolone within 24 hours and 25 to 48 hours had significantly higher complete recovery rates, 66% (103/156) and 76% (128/168), than patients given no prednisolone, 51% (77/152) and 58% (102/177) (p = 0.008 and p = 0.0003, respectively). For patients treated within 49 to 72 hours of palsy onset, there were no significant differences. Patients aged 40 years or older had significantly higher complete recovery rates if treated with prednisolone, whereas patients aged younger than 40 years did not differ with respect to prednisolone treatment. However, synkinesis was significantly less in patients younger than 40 years given prednisolone (p = 0.002).
CONCLUSION: Treatment with prednisolone within 48 hours of onset of palsy resulted in significantly higher complete recovery rates and less synkinesis compared with no prednisolone.
Authors:
Sara Axelsson; Thomas Berg; Lars Jonsson; Mats Engström; Mervi Kanerva; Anne Pitkäranta; Anna Stjernquist-Desatnik
Related Documents :
12560225 - Efficacy and safety of rituximab in type ii mixed cryoglobulinemia.
2046925 - Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with ...
17422385 - Canine pemphigus vulgaris treated with gold salt therapy.
11096695 - Giant cell arteritis.
19132245 - Extended perioperative thromboprophylaxis in patients with cancer. a systematic review.
21167675 - Outcome of primary total hip arthroplasty in charnley class c patients with juvenile id...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology     Volume:  32     ISSN:  1537-4505     ISO Abbreviation:  Otol. Neurotol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100961504     Medline TA:  Otol Neurotol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  141-6     Citation Subset:  IM    
Affiliation:
Department of Otorhinolaryngology-Head and Neck Surgery, Lund University Hospital, Lund, Sweden. sara.axelsson@skane.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Korbinian brodmann (1868-1918) and his contributions to mapping the cerebral cortex.
Next Document:  OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders.